Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.67 +3.7% SGZ 0.040 −11.1% GRSL 0.310 −3.1% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.67 +3.7% SGZ 0.040 −11.1% GRSL 0.310 −3.1%
Production / Operations Routine +

Avricore Health Achieves Milestones and Outlines UK Expansion Roadmap for HealthTab(TM) Platform

Avricore Health Scales UK NHS Pilot But Profitability Timeline Remains Distant

By The Northwire Desk — AI Analysis Apr 21, 2026 · 06:30 AVCR · 0.065 Avricore Health Inc.
Executive Summary
  • The most recent release (April 21, 2026) confirms operational milestones for the HealthTab™ platform in London community pharmacies.
  • Over 3,500 patients screened across North East and North Central London with a monthly per-location average 10 times higher than previous Canadian operations.
  • Strategic roadmap targets expansion to over 500 active UK locations by mid-2027, with an immediate target of more than 100 pharmacy sites in Q2 2026.
  • Financial projections indicate a return to profitability by Q3 2027 following a transition into the UK NHS market.
  • Revenue model shifts from testing fees to monthly subscription revenue expected in the second half of 2026.
  • Historical context shows progression from a November 2025 pilot launch (Barts Health NHS Trust) to January 2026 expansion announcements, culminating in this April milestone update.
Material Impact
  • The news validates previous strategic plans rather than introducing unexpected breakthroughs or major capital raises.
  • Operational metrics (3,500 patients screened) demonstrate scalability but do not yet translate to realized revenue as subscription models begin later in 2026.
  • Profitability target of Q3 2027 is a significant timeline extension from current operations, indicating continued cash burn risk before earnings generation.
  • The announcement aligns with the January expansion roadmap and November pilot integration, suggesting execution is on track but incremental.
  • No material negative surprises regarding regulatory hurdles or partnership cancellations were noted in this release.
AVCR · Price
Company Overview
  • Avricore Health operates a point-of-care testing platform (HealthTab™) designed for community pharmacies.
  • Flagship project integrates analyzers with cloud software to enable real-time analytics and public-health reporting within NHS pathways.
  • Primary focus is shifting care from hospitals to community settings, specifically targeting cardiovascular risk screening and chronic condition management.
  • Platform includes instruments, workflows, training, and support, positioning itself as a turnkey solution for pharmacy-based testing.
Read the original news release →

More from Avricore Health Inc.

Jun 17, 2026 · 06:30

Avricore Health Closes $1.254 Million Financing

Financings May 20, 2026 · 06:55

Avricore Health Raises $1.25M Amidst UK Expansion Push; Dilution Concerns Loom

Financings Jan 14, 2026 · 09:46

HealthTab(TM) to Expand Across North East London

Production / Operations Nov 27, 2025 · 19:09

Avricore's HealthTab supports inclisiran delivery

M&A / Property Nov 27, 2025 · 17:00

HealthTab(TM) to Power NHS Pilot

Production / Operations Jul 10, 2025 · 16:38

Avricore expands HealthTab to north-central London

M&A / Property